帕金森病的自标志物,认知缺陷和抑郁症状在帕金森病的症状
Yanzhe Li1, Hechao Yang1,2, Peng Zhao3
1Laboratory of Biological Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Hexi District, Tianjin, 300222, China.
Journal of neural transmission (Vienna, Austria : 1996)
|October 6, 2023
概括
自标志物LC3-II/LC3-I与帕金森病 (PD) 患者的抑郁症状有关. 在患有抑郁症的PD患者中,p62/SQSTM1与认知障碍有关,特别是命名和回忆.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 临床神经学 临床神经学
背景情况:
- 在帕金森病 (PD) 中,抑郁症状很普遍,影响患者的生活质量.
- 自,一种细胞降解过程,已经涉及到PD的发病和抑郁症.
- 以前的研究还没有完全阐明自标志物在PD患者群体中抑郁症状的表现中的特定作用.
研究的目的:
- 调查血自标志物 (LC3-I,LC3-II,p62/SQSTM1) 与帕金森病患者抑郁症状之间的关联.
- 探索这些自标志物,认知功能和PD中的抑郁状态之间的关系.
- 为了确定PD患者抑郁症状的潜在生物标志物.
主要方法:
- 163名帕金森病患者 (年龄在50-80岁) 被招募参加这项研究.
- 量化了自标志物 (LC3-I,LC3-II,p62/SQSTM1) 的血水平.
- 评估了抑郁症状 (HAMD-17),认知功能 (MoCA) 和运动功能 (MDS-UPDRS-III).
主要成果:
- 最初在抑郁和非抑郁的PD患者之间没有发现自性标志物的显著差异.
- 在调整了混因素后,LC3-II/LC3-I比率独立与PD患者的抑郁症状相关 (p=0.014).
- 在患有抑郁症的PD患者中,p62/SQSTM1与整体认知功能 (MoCA得分,p=0.020) 有显著的关联,特别是命名能力和延迟回忆 (p=0.017).
结论:
- LC3-II/LC3-I比率可以作为帕金森病中抑郁症状的潜在指标.
- 自标志物p62/SQSTM1与认知障碍有关,特别是在患有抑郁症的PD患者中命名和延迟回忆方面.
- 这些发现突显了帕金森病中自,情绪和认知之间的复杂联系,为进一步的生物标志物研究提供了途径.
相关概念视频
01:15Parkinson's Disease: Overview
587
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
587
01:24Parkinson's Disease: Treatment
287
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
287
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:26Alzheimer's Disease: Overview
506
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
506
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K